Other languages IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
40.65 ^USD	+1.78%		+8.14%	+14.25%

22/04	IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy	MT
22/04	IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer	22/04
IDEAYA Biosciences, Merck Sign Deal to Evaluate IDE161 in Combination with Keytruda to Treat Endometrial Cancer Patients	12/03
IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer	12/03
IDEAYA Biosciences Q4 Loss Widens, Revenue Declines	20/02
IDEAYA Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/02
IDEAYA Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/02
Ideaya Biosciences Insider Sold Shares Worth $4,495,550, According to a Recent SEC Filing	13/02
Ideaya Biosciences Insider Sold Shares Worth $350,371, According to a Recent SEC Filing	20/12
Ideaya Biosciences Insider Sold Shares Worth $2,627,618, According to a Recent SEC Filing	20/12
Ideaya Biosciences, Inc. Announces Clinical Study Collaboration with Gilead Sciences, Inc. to Evaluate Trodelvy and Ide397 Combination in Mtap-Deletion Bladder Cancer	04/12
IDEAYA Biosciences, Inc. Enters into an Office Lease Agreement with AAT TORREY 13-14, LLC to Expand Its Current Office Space in San Diego	17/11
Ideaya Biosciences Insider Sold Shares Worth $155,360, According to a Recent SEC Filing	08/11
IDEAYA Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline	23/23/23
IDEAYA Biosciences Initiates Phase 2 Expansion of Combination Therapy for Metastatic Cutaneous Melanoma	16/23/16
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	26/23/26
Ideaya Biosciences, Inc. Receives Fast Track Designation for Potential First-In-Class Parg Inhibitor, Ide161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients Having Tumors with Brca1/2 Mutations	26/23/26
Sector Update: Health Care Stocks Gaining Late Afternoon	22/23/22
Sector Update: Health Care Stocks Advancing Monday Afternoon	22/23/22
IDEAYA Biosciences Says US FDA Cleared Investigational New Drug Application for GSK-Sponsored Solid Tumor Therapy Trial	21/23/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Other languages

Filters